Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 28, 2017; 23(16): 2854-2869
Published online Apr 28, 2017. doi: 10.3748/wjg.v23.i16.2854
Published online Apr 28, 2017. doi: 10.3748/wjg.v23.i16.2854
Table 2 Eradication rates achieved with susceptible guided therapy as first treatment and rescue treatment
Line of therapy | Ref. | Type of therapy | Patients (n) | Methods | Tailored therapy eradication rates | |
ITT % | PP % | |||||
First Line | Liu et al[83], 2015 | RpzBAC, RpzBAF | 89 | Real-time PCR | 98 in RpzBAC group | 100 in RpzBAC group |
92.6 in RpzBAF group | 94 in RpzBAF group | |||||
First Line | Sugimoto et al[90], 2014 | RpzAC, RpzAM | 153 | PCR | 96.7 (overall) | 97.4 (overall) |
Third line | Liou et al[89], 2013 | Sequential triple | 135 | PCR and Agar dilution | 80.7 | 82.6 |
Fourth | Fiorini et al[91], 2013 | Triple (EAC, EAR) | 236 | E-test | NR | 90 in EAC |
88.6 in EAR |
- Citation: Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017; 23(16): 2854-2869
- URL: https://www.wjgnet.com/1007-9327/full/v23/i16/2854.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i16.2854